Kennedy Capital Management LLC Sells 222,426 Shares of Personalis, Inc. $PSNL

Kennedy Capital Management LLC cut its holdings in Personalis, Inc. (NASDAQ:PSNL) by 11.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,712,652 shares of the company’s stock after selling 222,426 shares during the period. Kennedy Capital Management LLC’s holdings in Personalis were worth $13,633,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Deutsche Bank AG lifted its position in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the period. Howland Capital Management LLC lifted its holdings in shares of Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after buying an additional 2,500 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Personalis by 184.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after buying an additional 3,592 shares during the period. Finally, Intech Investment Management LLC lifted its holdings in shares of Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after buying an additional 3,851 shares during the period. 61.91% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Christopher M. Hall sold 80,091 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $11.02, for a total value of $882,602.82. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $2,600,565.72. This trade represents a 25.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $12.01, for a total value of $480,400.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,387,984.33. This represents a 16.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 178,799 shares of company stock worth $2,031,692. 4.20% of the stock is owned by insiders.

Analyst Ratings Changes

PSNL has been the topic of several research analyst reports. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Morgan Stanley lowered their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Personalis Stock Performance

Shares of Personalis stock opened at $9.59 on Monday. Personalis, Inc. has a one year low of $3.84 and a one year high of $12.53. The stock’s fifty day moving average is $7.55 and its 200 day moving average is $8.25. The stock has a market cap of $1.00 billion, a P/E ratio of -9.40 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. Analysts predict that Personalis, Inc. will post -1.06 EPS for the current year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.